The last couple of quarters have been very favorable for Eli Lilly and Company (NYSE:LLY) and its position in the obesity and adjacent markets. The main competitor Novo Nordisk A/S (NVO ...

Global pharmaceutical company Eli Lilly (NYSE:LLY) will be reporting results tomorrow before market hours. Here’s what to look for. Eli Lilly met analysts’ revenue expectations last quarter ...

Eli Lilly is paying $13 million upfront, with $1 billion in biobucks up for grabs, for the opportunity to develop AI-designed oligonucleotide therapies from Creyon Bio. Oligonucleotides work as ...

Eli Lilly is scheduled to report its quarterly results on May 1. The company may report its Q1 results in line with peers. Don't face extreme market conditions unprepared. Get the professional ...

Pharmaceutical giant Eli Lilly and Co. sued Willow Health Services and three other companies in federal court in New Jersey and California, accusing them of selling unapproved compounded ...

Given the potential opportunities in the sector, should investors buy Eli Lilly stock? Here's where the company and its stock stand now. The GLP-1 agonist opportunity is gearing up for its next ...

April 23 (UPI) --Eli Lilly Wednesday filed lawsuits against four telehealth companies alleging they are deceiving consumers by selling compounds of slightly-different versions of Lilly drugs.

Eli Lilly is suing four telemedicine companies selling compounded versions of its blockbuster obesity drug Zepbound and its diabetes treatment Mounjaro, escalating its battle against unauthorized ...

Pharmaceutical company Eli Lilly announced promising clinical trial results this week for a daily pill to treat obesity and diabetes. Besides the good news of minimal side effects and impressive ...

Eli Lilly is suing four telehealth companies that prescribe compounded versions of the pharmaceutical company's weight loss medications. Lilly filed four lawsuits on Wednesday claiming telehealth ...